Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PROSPANTUS JARABE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/PROSPANTUS JARABE

Approved

STANDARD

PROSPANTUS JARABE

Elam Pharma Labs S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 24, 2024
Approval ID: baeab4d7930eff24
Company: Elam Pharma Labs S.L.
Type: Standard

Approval Details

Approval Id: baeab4d7930eff24
Drug Cima Aemps Name: PROSPANTUS JARABE
Register Number: 1213620190102
Holder Company Name: Elam Pharma Labs S.L.
Marketing Company Name: Elam Pharma Labs S.L.
Authorization Date: 2024-06-24
Dosage Form: JARABE
Dose: 7 mg yedra exto seco/ ml
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: No
Company Name: Elam Pharma Labs S.L.

Active Ingredients

HEDERA HELIX L. EXTRACTO SECO

7 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 24, 2024

Approval ID

baeab4d7930eff24

Type

Standard

Back to CIMA-AEMPS Approvals